Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report 2026

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview

• Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs market size has reached to $35.66 billion in 2025 • Expected to grow to $55.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Increasing Prevalence Of Smoking Is Fueling The Market Due To Rising Respiratory Health Complications • Market Trend: Integration Of Dual-Action Rescue Therapies In Respiratory Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Asthma and chronic obstructive pulmonary disease (COPD) drugs are medications used to manage and treat respiratory conditions that cause breathing difficulties. These drugs help to reduce inflammation, relax airway muscles, and improve airflow to the lungs, thereby easing symptoms such as wheezing, coughing, and shortness of breath. These medications are typically administered via inhalers or nebulizers for effective lung delivery. The main drug classes used for asthma and COPD drugs include bronchodilators, corticosteroids, combination drugs, and leukotriene modifiers. Bronchodilators are medications that quickly relax the airway muscles to widen breathing passages, providing fast relief from asthma and COPD symptoms. These drugs are administered through various routes, including inhalation, oral, injection, nasal, and other methods. They are prescribed to different patient groups, such as adults, pediatrics, and geriatrics, and are used for multiple applications including asthma, COPD, allergic rhinitis, and pulmonary hypertension. The distribution of these medications occurs through several channels such as hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

What Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Forecast?

The asthma and chronic obstructive pulmonary disease (copd) drugs market size is expected to see strong growth in the next few years. It will grow to $55.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to biologic drug innovation, aging population, air quality deterioration, personalized respiratory medicine, homecare respiratory solutions. Major trends in the forecast period include increased use of combination inhaler therapies, growing adoption of long-acting bronchodilators, expansion of biologic therapies for severe asthma, shift toward home-based respiratory management, rising demand for generic inhalation drugs.

Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmentation

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers 2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations 3) By Patient Group: Adult, Pediatric, Geriatric 4) By Application: Asthma, Chronic Obstructive Pulmonary Disease 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores Subsegments: 1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines 2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids 3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid 4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Is The Driver Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The increasing prevalence of smoking is expected to propel the growth of the asthma and COPD drugs market going forward. Smoking refers to the habit of consuming tobacco products by inhaling the smoke, which can lead to serious health issues such as lung cancer and heart disease. The increasing prevalence of smoking is primarily driven by social influence, where peer pressure, cultural norms, and social environments encourage individuals to start and continue smoking. Asthma and chronic obstructive pulmonary disease (COPD) drugs help mitigate the respiratory damage caused by smoking by reducing inflammation, relaxing airway muscles, and improving airflow, thereby alleviating symptoms and enhancing lung function. For instance, in 2024, according to the European Respiratory Society's (ERS), a Switzerland-based non-profit organization, a study on smoking trends among young people showed a notable increase in smoking rates, rising from 22.5% of respondents in 2022 to 40.1% in 2024. Therefore, the increasing prevalence of smoking is driving the growth of the asthma and COPD drugs market.

Key Players In The Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Trends and Insights

Major companies operating in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are focusing on incorporating innovative drug-combination therapies such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers to enhance benefits like preventing severe asthma attacks, improving inflammation control, and supporting better overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which rapidly relaxes airway muscles to relieve symptoms, with an inhaled corticosteroid, which reduces underlying airway inflammation, enabling dual capabilities such as immediate symptom relief alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US, a fixed-dose SABA-ICS rescue inhaler designed to treat asthma symptoms and help prevent sudden severe breathing problems, featuring its dual-component formulation delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while simultaneously addressing airway inflammation, thereby reducing the risk of severe asthma exacerbations and enhancing overall asthma control.

What Are Latest Mergers And Acquisitions In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

In February 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Biofor an undisclosed amount. Through this acquisition, GSK aims to expand its asthma and respiratory biologics portfolio by integrating Aiolos Bio’s investigational therapy, AIO‑001, a long-acting anti-TSLP monoclonal antibody designed for adult patients with severe asthma, including those with low T2 inflammation. Aiolos Bio Inc. is a US-based biotech developing innovative treatments for unmet needs in respiratory conditions.

Regional Insights

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report 2026?

The asthma and chronic obstructive pulmonary disease (copd) drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the asthma and chronic obstructive pulmonary disease (copd) drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.